| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
2 companies
Adams Catherine Owen is Chief Executive Officer at ACAD and has filed Form 4s across 2 companies. Adams Catherine Owen's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $643K at current prices.
The biggest single holding is AGIO (~$339K) as Director.
Adams Catherine Owen has 11 Form 4 filings on record from June 2023 to June 2026, across 2 companies: Director at Agios Pharmaceuticals (AGIO), 2023–2026; Chief Executive Officer at ACADIA Pharmaceuticals (ACAD), 2024–2026.
The 20 reported transactions were 13 option or other derivative awards, 6 option exercises and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $250K.
The only open-market sale was 11,641 shares of ACAD at an average $21.47 on March 25, 2026, about $250K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | ACAD Acadia Pharmaceuticals Inc. | Chief Executive Officer | Sale+OE | 11,641 | $21.47 | $249,932.27 | -44.0% | +2.7% | - |